Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis.
The use of icodextrin as an osmotic agent in solutions for peritoneal dialysis (PD) has important cardiovascular effects related with better control of extracellular volume. Among them, reduction of arterial pressure and an improvement in echocardiographic parameters stand out. In diabetic patients, icodextrin has additional potential advantages related with better metabolic control. In a multicenter, open-label randomized controlled trial, the effects of icodextrin solutions were compared to glucose solutions on echocardiographic, electrocardiographic, and blood pressure changes in diabetic patients on PD. Two phases were noted in the follow-up. In the early phase (6 months), reduction in ambulatory blood pressure (ABP) and left ventricular end diastolic diameter were found in the icodextrin group. These changes correlated with changes in body fluids. In the late phase (12 months), a trend towards baseline values in ABP was seen. Changes in inferior vena cava diameter and in low frequency R-R variability spectral analysis in the icodextrin group suggest that icodextrin increases circulating blood volume and sympathetic tone, probably by accumulation of icodextrin metabolites in the bloodstream and improvement in diabetic neuropathy as a result of lower peritoneal glucose absorption. The effects of icodextrin in diabetic patients were related to better fluid management and metabolic control.
Paniagua
R
R
Unidad de Investigación Médica en Enfermedades Nefrológicas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México. jpaniaguas@cis.gob.mx
Orihuela
O
O
Ventura
M-D-J
MD
Avila-Díaz
M
M
Cisneros
A
A
Vicenté-Martínez
M
M
Furlong
M-D-C
MD
García-González
Z
Z
Villanueva
D
D
Prado-Uribe
M-D-C
MD
Alcántara
G
G
Amato
D
D
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D001810:Blood Volume / Q000187:drug effects / Q000502:physiology; D048909:Diabetes Complications / Q000150:complications / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000628:therapy*; D015314:Dialysis Solutions / Q000494:pharmacology*; D004562:Electrocardiography; D005260:Female; D005936:Glucans / Q000494:pharmacology*; D005947:Glucose / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006352:Heart Ventricles / Q000000981:diagnostic imaging*; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000379:methods*; D014463:Ultrasonography; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology
D015314:Dialysis Solutions; D005936:Glucans; D000077607:Icodextrin; D005947:Glucose